📊 This is a company profile preview from Tablestat.com Request a Free Trial Now

Company profile: NexImmune

1.1 - Company Overview

NexImmune Logo

NexImmune

Headquarter: United States
Founded: 20XX🔒
Employees: 100-500🔒

Company description

  • Provider of immuno-therapeutics using proprietary AIM artificial immune technology, including AIM ACT, a cellular therapy using AIM nanoparticles to orchestrate specific T cell functions for cancer treatment; AIM INJ, an injectable AIM nanoparticle product targeting disease-specific T cells; and Phase 1/2 candidates NEXI-001 (AML) and NEXI-002 (multiple myeloma).

Products and services

  • AIM ACT: Nanoparticle-based cellular therapy product engineered with AIM nanoparticle technology to orchestrate specific T cell functions, designed specifically for the treatment of cancer
  • AIM INJ: Injectable-form pharmaceutical product comprising AIM nanoparticles, targeting disease-specific T cells for direct injection or infusion
  • NEXI-001: Clinical-stage product candidate leveraging AIM technology for treating acute myeloid leukemia (AML) in Phase 1/2 clinical development

Key contacts

🔒
🔒

Financial details

🔒

1.2 - Competitors and similar companies to NexImmune

Synaffix Logo

Synaffix

HQ: The Netherlands Website
  • Description: Provider of a proprietary antibody-drug conjugate (ADC) technology platform enhancing efficacy and tolerability to treat cancer and other disorders, enabling development from any antibody. Offerings include GlycoConnect for stable ADCs, HydraSpace for improved payload performance, toxSYN linker-payloads, conversion of antibodies to bispecifics, and custom payload delivery (cytokines, TLR/STING agonists, oligonucleotides, peptides, antibiotics, cytotoxics).
  • Rationale: This competitor operates in a highly similar market segment with overlapping features.
  • Company type: Private company
  • Employees: ●●●●●
  • Total funding raised: $●●●m
  • Backers: ●●●●●●●●●●
  • Acquisitions: ●●
View full Synaffix company profile →
Vaccinogen Logo

Vaccinogen

HQ: United States Website
  • Description: Provider of vaccines and other immunotherapeutic products for cancers and infectious diseases.
  • Rationale: This competitor operates in a highly similar market segment with overlapping features.
  • Company type: Private company
  • Employees: ●●●●●
  • Total funding raised: $●●●m
  • Backers: ●●●●●●●●●●
  • Acquisitions: ●●
View full Vaccinogen company profile →
Y-mAbs Therapeutics Logo

Y-mAbs Therapeutics

HQ: United States Website
  • Description: Provider of innovative cancer treatments and support services, including FDA-approved DANYELZA (naxitamab-gqgk) for relapsed or refractory high-risk neuroblastoma in bone or bone marrow; clinical trials for investigational therapies (naxitamab, omburtamab, GD2-SADA); expanded access programs; Y-mAbs Connect for access, insurance and financial support; and patient and family resources.
  • Rationale: This competitor operates in a highly similar market segment with overlapping features.
  • Company type: Private company
  • Employees: ●●●●●
  • Total funding raised: $●●●m
  • Backers: ●●●●●●●●●●
  • Acquisitions: ●●
View full Y-mAbs Therapeutics company profile →
GlobeImmune Logo

GlobeImmune

HQ: United States Website
  • Description: Provider of a proprietary Tarmogen® platform used to develop products for the treatment of cancer and infectious diseases.
  • Rationale: This competitor operates in a highly similar market segment with overlapping features.
  • Company type: Private company
  • Employees: ●●●●●
  • Total funding raised: $●●●m
  • Backers: ●●●●●●●●●●
  • Acquisitions: ●●
View full GlobeImmune company profile →
Xilio Therapeutics Logo

Xilio Therapeutics

HQ: United States Website
  • Description: Provider of tumor-activated immuno-oncology therapies, including XTX101, an Fc-enhanced anti-CTLA-4 monoclonal antibody; XTX301, an engineered IL-12; XTX202, a tumor-selective protein-engineered IL-2; and XTX501, a tumor-activated PD1/IL2 bispecific, designed to enhance anti-tumor activity, reprogram the tumor microenvironment, improve tolerability, minimize peripheral toxicities, and overcome IL-2 receptor-mediated clearance.
  • Rationale: This competitor operates in a highly similar market segment with overlapping features.
  • Company type: Private company
  • Employees: ●●●●●
  • Total funding raised: $●●●m
  • Backers: ●●●●●●●●●●
  • Acquisitions: ●●
View full Xilio Therapeutics company profile →
🔒

2.M&A buyers

2.1 Potential strategic acquirers in the sector

🔒
🔒
🔒
🔒 View all strategic buyers with complete profiles
Start Free Trial →

2.2 - Strategic buyer groups for NexImmune

🔒

Buyer group 1: ████████ ████████

●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒 View all companies in this group
Request Free Trial Now →
🔒

Buyer group 2: ████████ ████████

●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒 View all companies in this group
Request Free Trial Now →
🔒

Buyer group 3: ████████ ████████

●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒 View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →

3. Investors and private equity firms

3.1 - Buyout funds investing in similar companies to NexImmune

2.2 - Growth funds investing in similar companies to NexImmune

🔒 View all growth equity funds with complete profiles
Start Free Trial →

4 - Top valuation comps for NexImmune

4.2 - Public trading comparable groups for NexImmune

🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →

4.3 - M&A Transactions similar to NexImmune

Selected M&A transactions

Date Target Description Buyer(s) Relevance EV EV/Revenue EV/EBITDA
🔒 View all M&A transactions with complete deal terms
Request Free Trial Now →

Frequently Asked Questions

About NexImmune

What does NexImmune do?

NexImmune is a provider of immuno-therapeutics using proprietary AIM artificial immune technology, including AIM ACT, a cellular therapy using AIM nanoparticles to orchestrate specific T cell functions for cancer treatment; AIM INJ, an injectable AIM nanoparticle product targeting disease-specific T cells; and Phase 1/2 candidates NEXI-001 (AML) and NEXI-002 (multiple myeloma).

Who are NexImmune's competitors?

NexImmune's competitors and similar companies include Synaffix, Vaccinogen, Y-mAbs Therapeutics, GlobeImmune, and Xilio Therapeutics.

Where is NexImmune headquartered?

NexImmune is headquartered in United States.

How many employees does NexImmune have?

NexImmune has 1,000 employees 🔒.

When was NexImmune founded?

NexImmune was founded in 2010 🔒.

What sector and industry vertical is NexImmune in?

NexImmune is in the Enterprise Software 🔒 sector and industry

M&A Buyers & Acquirers for NexImmune

Who are the top strategic acquirers in NexImmune's sector and industry

Top strategic M&A buyers and acquirers in NexImmune's sector include ████████, ██████████, ██████, ████████, and ██████████ 🔒.

Which M&A buyer groups are most relevant for NexImmune?

Top strategic M&A buyers groups and sectors for NexImmune include █████████████████ , ████████████████, █████████████, ████████████, and ████████████████ 🔒.

Financial Investors investing in NexImmune's sector and industry vertical

Which are the top PE firms investing in NexImmune's sector and industry vertical?

Top PE firms investing in NexImmune's sector and industry vertical include ████████, ██████████, ████████, and ██████████ 🔒.

Who are the top buyout funds acquiring in NexImmune's sector and industry vertical?

Active PE funds and buyout funds acquiring companies in NexImmune's sector and industry vertical include █████████, ██████████, ████████████, and ████████████ 🔒.

Who are the top growth equity funds investing in companies in NexImmune's sector and industry vertical?

Growth funds and venture capital funds investing in companies similar to NexImmune include █████████, ██████████, ████████████, and ████████████ 🔒.

Valuation benchmarks of companies in NexImmune's sector and industry

Which are the key public companies that are relevant trading comps benchmarks for NexImmune?

The key public trading comparables and valuation benchmarks for NexImmune include █████████, ██████████, ████████████, and ████████████ 🔒.

Which are the key trading comparable groups for NexImmune for public valuation benchmarks?

Our platform tracks detailed public trading comparable groups and valuation benchmarks for NexImmune with complete valuation multiples, growth metrics, and profitability data. Access the full database to benchmark your company against relevant public comparables.

What are recent M&A transactions in NexImmune's sector and industry vertical?

Our platform tracks relevant M&A transactions comparables and valuation benchmarks for NexImmune with complete deal terms, valuation multiples, and strategic rationale. Access the full database to benchmark pricing and identify active acquirers.

What are recent capital raises and funding rounds in NexImmune's' sector and industry vertical?

Access recent funding rounds and capital raises in NexImmune's sector and industry vertical including growth equity, venture capital, and buyout investments. Our database includes round size, lead investors and valuations.

Ready to Find the Right Buyers?

Access complete buyer lists, valuation data, and M&A intelligence for NexImmune